BioVie Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	8.79	8.57	8.85	11.55	9.77	4.64
Research & Development	10.21	9.27	23.1	33.3	17.26	133.19
Amortization of Goodwill & Intangibles	0.23	0.23	0.23	0.23	0.23	0.23
Operating Expenses	19.23	18.07	32.18	45.08	27.25	138.05
Operating Income	-19.23	-18.07	-32.18	-45.08	-27.25	-138.05
Interest Expense	-0.08	-0.33	-2.89	-4.3	-2.16	-0.56
Interest & Investment Income	0.83	0.85	1.14	0.56	0.04	0.02
Other Non Operating Income (Expenses)	0	0	1.82	-1.44	3.29	8.28
EBT Excluding Unusual Items	-18.48	-17.54	-32.12	-50.26	-26.08	-130.31
Other Unusual Items	-	-	-	-	-	0.06
Pretax Income	-18.48	-17.54	-32.12	-50.26	-26.08	-130.25
Net Income	-18.48	-17.54	-32.12	-50.26	-26.08	-130.25
Preferred Dividends & Other Adjustments	0.09	0.37	0.89	-	-	53.6
Net Income to Common	-18.57	-17.91	-33.01	-50.26	-26.08	-183.85
Shares Outstanding (Basic)	3	1	0	0	0	0
Shares Outstanding (Diluted)	3	1	0	0	0	0
Shares Change (YoY)	404.04%	226.96%	39.10%	31.71%	98.84%	151.61%
EPS (Basic)	-7.08	-12.12	-73.05	-154.71	-105.77	-1482.26
EPS (Diluted)	-7.08	-12.12	-73.05	-154.71	-106.00	-1482.26
EBITDA	-19	-17.84	-31.95	-44.85	-27.02	-137.82
D&A For EBITDA	0.23	0.23	0.23	0.23	0.23	0.23
EBIT	-19.23	-18.07	-32.18	-45.08	-27.25	-138.05

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q